Full-Time

Oncology Early Stage Clinical Scientist

Director, Non-MD

Posted on 11/23/2025

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$169.7k - $282.9k/yr

+ Bonus + Long Term Incentive + Pfizer 401(k) + Retirement Savings Contribution

Cambridge, MA, USA + 5 more

More locations: Bothell, WA, USA | San Bruno, CA, USA | La Jolla, San Diego, CA, USA | Groton, CT, USA | New York, NY, USA

Hybrid

US Top Secret Clearance Required

Category
Biology & Biotech (2)
,
Required Skills
Data Analysis
Google Cloud Platform
Requirements
  • Relevant PhD or PharmD and a minimum of 5 years of experience in a similar role in industry/CRO, OR
  • MS and a minimum of 7 years of experience in a similar role in industry/CRO, OR
  • BA/BS and a minimum of 10 years of experience in a similar role in industry/CRO
  • Clinical Research experience in Phase 1 in Oncology, on the side of the sponsor leading studies
  • Experience in or strong understanding of Oncology Drug Development especially in Early Development
  • Strong knowledge of clinical procedures, ICH guidelines, GCP and familiarity with FDA, EMA, and global regulations
  • Strong scientific writing skills and communication skills (written and verbal)
  • Clinical document writing experience (e.g., protocol, ICD, IB, IND), as well as understanding complex data analysis
  • Track record of scientific productivity as evidenced by publications, posters, abstracts and/or presentations
  • Experience working with and solid understanding of related disciplines, e.g., Clinical Operations, Safety, Biostatistics, Regulatory, Study Management, Pre-Clinical, Pharmacology, Quality Assurance
  • Experience building consensus and driving change across all levels of the organization including senior management
  • Data listing review experience
  • Critical thinker, with experience working collaboratively in a fast-paced, team-based matrix environment as well as working independently when appropriate
  • Experience performing complex data analyses using JReview, SpotFire, SOCs-PRO or other similar platform
Responsibilities
  • Partner closely with the Global Development Lead (GDL) in the execution of the clinical development strategy and plan for the assigned molecule(s)/indication(s)
  • Responsible for scientific leadership and execution of clinical studies and delivering on innovative clinical study designs, high quality trial execution, safety assessment and interpretation of clinical study results
  • Support execution for all FIH programs through proof-of concept
  • Set the clinical data review strategy, ensure quality data and conduct review of emerging clinical data and trends; review and query data; present and discusse relevant data to appropriate teams, governance bodies, and other internal and external stakeholders
  • Conduct data review, analysis and interpretation of clinical trials data together with the GDL, Clinical Safety, and Biostatistics
  • Serve as technical resource for clinical issues raised by internal and external collaborators, investigators, consultants and contractors
  • Support and assist in the development of publications, abstracts, and presentations
  • May sit on project teams to support clinical development implementation and contribution to key development milestones, e.g. start-up and delivery of ESoE and PoC trials
  • Participate in project teams to help implement clinical development and contribute to key milestones (e.g., start-up and delivery of early signs of efficacy [ESoE] and POC trials)
  • Lead the preparation of clinical protocols and support other critical documents including clinical development plans, INDs, annual reports, clinical study reports (CSRs), investigator brochures, statistical analysis plans, and regulatory documents
  • Foster a transparent environment that builds strong partnerships and mutual trust among teams and therapeutic areas
  • Coordinate with other clinical research activities within Oncology Research Development (ORD) and the broader Worldwide Research and Development (WRD) organization
  • Develop effective collaborations with key internal and external partners, such as project leaders, research units, biostatistics, regulatory affairs, clinical pharmacology, human genetics, translational oncology, precision medicine, and development operations
  • Partner with Translational Oncology and Biomarker teams to ensure biomarker plans are integrated into relevant programs for early efficacy signs and POC, as well as patient stratification
  • Establish and support relationships with external experts, consultants, key opinion leaders, regulators, and investigator networks to integrate the latest clinical thinking and guidelines into development plans and study designs, as well as manage study recruitment, analysis, interpretation, and presentation of results
  • Maintain up-to-date knowledge of scientific and clinical literature in relevant therapeutic areas, including key clinical development issues
  • Perform other duties as assigned related to clinical programs
  • Support functional area priorities and contribute to or lead departmental initiatives as requested
Desired Qualifications
  • Experience leading a team
  • Demonstrates diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Berobenatide could create a differentiated obesity franchise if Phase 3 succeeds.
  • The 25-valent pneumococcal vaccine can extend Pfizer's vaccine leadership beyond Prevnar.
  • AI licensing with Chai Discovery may accelerate early-stage drug design and hit rates.

What critics are saying

  • Eliquis, Ibrance, and Xtandi patent expirations will pressure revenue before replacements mature.
  • Berobenatide faces entrenched GLP-1 competition and a costly 10-plus-trial Phase 3 program.
  • Pfizer's oncology strategy depends on late-stage execution across dozens of programs and partnerships.

What makes Pfizer unique

  • Pfizer directs about 40% of R&D into oncology across five tumor areas.
  • Its oncology pipeline spans 50+ programs, 25+ new molecular entities, and 3 modalities.
  • HYMPAVZI is the first subcutaneous non-factor therapy for pediatric hemophilia B ages 6-11.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.

INACTIVE